Form 4: Edwards Lifesciences CEO Exercises Options, Sells Shares

Edwards Lifesciences CEO Bernard J. Zovighian exercised stock options and sold a portion of his common stock holdings in pre-planned transactions.

Summary

• Bernard J. Zovighian, CEO and Director of Edwards Lifesciences Corp, engaged in multiple transactions involving the company's common stock and employee stock options.
• On December 8, 2025, he exercised 25,350 employee stock options at an exercise price of $59.2567 per share, acquiring common stock.
• On the same day, he sold 21,487 shares of common stock at a weighted average price of $85.2146 per share, with prices ranging from $84.63 to $85.57.
• On December 9, 2025, 3,863 shares of common stock were transferred (disposed of at $0.0000) from direct ownership and simultaneously acquired indirectly by a Trust.
• On December 10, 2025, the Trust disposed of 3,863 shares of common stock at $83.45 per share.
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025.
• Following these transactions, Zovighian directly owns 80,976 shares of common stock, indirectly owns 8,596.5511 shares through a Trust, and 3,605.8487 shares in a 401(k) plan.
• He also continues to beneficially own 25,350 employee stock options with an exercise price of $59.2567, which were granted on May 8, 2019, and are scheduled to expire on May 7, 2026.

Sentiment

Score: 5

Explanation: The transactions are routine for an executive, involving the exercise of options and subsequent sale of shares, all under a pre-planned 10b5-1 arrangement. This typically has a neutral sentiment as it is not indicative of new positive or negative company developments.

Positives

• The exercise of stock options indicates a realization of value from previously granted equity compensation.
• The transactions were conducted under a Rule 10b5-1 trading plan, indicating they were pre-scheduled and not based on immediate, non-public information.

Negatives

• The sale of common stock by a high-ranking executive, even if pre-planned, reduces their direct equity stake in the company.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

This filing is a routine disclosure of insider transactions and does not provide information to analyze broader industry trends or competitors.

Related Party Transactions

• Bernard J. Zovighian, CEO and Director, exercised employee stock options and sold common stock.
• Shares were transferred to and subsequently sold by a Trust associated with the Reporting Person.

Stakeholder Impact

• Shareholders: The sale of shares by the CEO, even if pre-planned, slightly increases the supply of shares in the market. However, the Rule 10b5-1 plan mitigates concerns about opportunistic selling.
• Employees: No direct impact on employees is indicated.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated.

Key Dates

Recommendation

The filing details routine insider transactions (option exercise and share sales) conducted under a pre-established Rule 10b5-1 plan. Such transactions are generally not indicative of new material information about the company's performance or outlook. Therefore, they do not provide a basis for changing an investment recommendation. An investor would typically hold their position unless other fundamental or market-related factors suggest a change.

Keywords

Edwards Lifesciences, EW, Bernard J Zovighian, CEO, Director, Form 4, insider trading, stock options, common stock, Rule 10b5-1 plan, equity compensation, share sale